Get the Stockscreener App
16.62
2.65%
0.355
Tourmaline Bio Inc stock is traded at $16.62, with a volume of 46,444.
It is up +2.65% in the last 24 hours and up +27.59% over the past month.
Tourmaline Bio Inc is a late-stage clinical biotechnology company driven by its mission to develop transformative medicines that dramatically improve the lives of patients with life-altering immune diseases. Its initial product candidate is TOUR006, a fully human monoclonal antibody that selectively binds to interleukin-6 (IL-6), a key proinflammatory cytokine involved in the pathogenesis of many autoimmune and inflammatory disorders. The anti-IL-6 and anti-IL-6 receptor (IL-6R) antibody class (IL-6 class) has over two decades of clinical and commercial experience treating over a million patients with a variety of autoimmune and inflammatory diseases.
See More
Previous Close:
$16.27
Open:
$16.46
24h Volume:
46,444
Relative Volume:
0.19
Market Cap:
$421.44M
Revenue:
-
Net Income/Loss:
$11.77M
P/E Ratio:
28.74
EPS:
0.5785
Net Cash Flow:
$-19.23M
1W Performance:
+16.55%
1M Performance:
+27.59%
6M Performance:
-13.33%
1Y Performance:
-63.21%
1-Day Range:
$16.34
$16.93
1-Week Range:
$13.85
$16.93
52-Week Range:
$11.87
$46.36
Tourmaline Bio Inc Stock (TRML) Company Profile
Name
Tourmaline Bio Inc
Sector
Industry
Phone
646-481-9832
Address
27 WEST 24TH STREET, NEW YORK
Compare TRML with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
TRML
Tourmaline Bio Inc
|
16.66 | 421.44M | 0 | 11.77M | -19.23M | 0.5785 |
|
VRTX
Vertex Pharmaceuticals Inc
|
500.61 | 130.96B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
683.38 | 75.53B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
578.00 | 35.07B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
241.17 | 31.72B | 2.25B | -278.16M | -42.59M | -2.17 |
|
ONC
Beigene Ltd Adr
|
249.50 | 26.76B | 3.32B | -860.46M | -1.04B | -8.32 |
Tourmaline Bio Inc Stock (TRML) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Mar-06-25 | Initiated | Wedbush | Outperform |
| Dec-06-24 | Initiated | BMO Capital Markets | Outperform |
| Nov-11-24 | Reiterated | H.C. Wainwright | Buy |
| Dec-15-23 | Initiated | Jefferies | Buy |
| Dec-04-23 | Resumed | H.C. Wainwright | Buy |
| Nov-17-23 | Initiated | Truist | Buy |
| Oct-31-23 | Initiated | Guggenheim | Buy |
| Oct-25-23 | Initiated | Piper Sandler | Overweight |
| Oct-20-22 | Initiated | H.C. Wainwright | Buy |
| Jul-05-22 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
View All
Tourmaline Bio Inc Stock (TRML) Latest News
Tourmaline Bio, Inc. SEC 10-K Report - TradingView
Tourmaline Bio Reports Fourth Quarter and Full Year 2024 Financial Results and Recent Business Highlights - The Manila Times
Tourmaline Bio's cash position to provide cash runway into second half of 2027 -March 13, 2025 at 07:39 am EDT - Marketscreener.com
Tourmaline Bio Reports Fourth Quarter and Full Year 2024 Financial Results and Recent Business ... - Bluefield Daily Telegraph
Tourmaline Bio Secures 2.5-Year Cash Runway with $294M, Accelerates Key Clinical Trials - StockTitan
Tourmaline Bio (TRML) Projected to Post Earnings on Tuesday - Defense World
Wedbush Forecasts Tourmaline Bio FY2024 Earnings - Defense World
Tourmaline Bio (NASDAQ:TRML) Research Coverage Started at Wedbush - Defense World
Rhumbline Advisers Has $722,000 Position in Tourmaline Bio, Inc. (NASDAQ:TRML) - Defense World
Tourmaline Bio rises as Wedbush initiates with Outperform - MSN
This Tourmaline Bio Analyst Begins Coverage On A Bullish Note; Here Are Top 3 Initiations For Thursday - NewsBreak
Wedbush bullish on Tourmaline Bio, initiates with an Outperform - TipRanks
Wedbush Initiates Coverage on Tourmaline Bio With Outperform Rating, $42 Price Target - Marketscreener.com
Wedbush Initiates Tourmaline Bio at Outperform With $42 Price Target -March 06, 2025 at 07:22 am EST - Marketscreener.com
We Tested Over 25 Curling Irons. These 13 Are the Best - MarieClaire.com
Tourmaline Bio to Present at the Leerink Partners Global Healthcare Conference 2025 - The Manila Times
Volatus Aerospace and Draganfly Expand Collaboration to Service High-Value Geospatial Power Utility Customers - The Manila Times
3 Reasons to Buy American Express Stock Like There's No Tomorrow - The Globe and Mail
When and Where to Catch Tourmaline Bio's Next Investor Presentation - StockTitan
Brokers Set Expectations for Tourmaline Bio FY2024 Earnings - MarketBeat
Truist maintains $74 target on Tourmaline Bio stock, reiterates buy By Investing.com - Investing.com UK
Lifesci Capital Predicts Tourmaline Bio FY2024 Earnings - Defense World
Financial Survey: X4 Pharmaceuticals (NASDAQ:XFOR) & Tourmaline Bio (NASDAQ:TRML) - Defense World
Tourmaline Bio (NASDAQ:TRML) Coverage Initiated by Analysts at Lifesci Capital - Defense World
LifeSci Capital Initiates Coverage of Tourmaline Bio (TRML) with Outperform Recommendation - MSN
Talaris Therapeutics stock hits 52-week low at $12.06 By Investing.com - Investing.com Australia
Talaris Therapeutics stock hits 52-week low at $12.06 - Investing.com
This Smithfield Foods Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Monday - Benzinga
Vaxcyte (NASDAQ:PCVX) & Tourmaline Bio (NASDAQ:TRML) Financial Review - Defense World
Tourmaline Bio, Inc. (NASDAQ:TRML) Receives $54.00 Average PT from Brokerages - MarketBeat
Tourmaline Bio, Inc. (NASDAQ:TRML) Given Average Recommendation of "Buy" by Analysts - MarketBeat
Tourmaline Bio, Inc. (NASDAQ:TRML) Given Average Recommendation of “Buy” by Analysts - Defense World
ClearOne (NASDAQ:CLRO) Earns Hold Rating from Analysts at StockNews.com - Defense World
StockNews.com Begins Coverage on Bank of South Carolina (NASDAQ:BKSC) - Defense World
Aethlon Medical (NASDAQ:AEMD) Raised to Sell at StockNews.com - Defense World
Tourmaline Bio, Inc. (NASDAQ:TRML) Short Interest Up 16.3% in January - MarketBeat
Vulcan Materials (VMC) Q4 Earnings: What To Expect - The Globe and Mail
TrueBlue (TBI) Expected to Announce Earnings on Wednesday - Armenian Reporter
Andersons (ANDE) Projected to Post Quarterly Earnings on Tuesday - Defense World
Leerink Partnrs Comments on Tourmaline Bio FY2024 Earnings - MarketBeat
Leerink Partnrs Weighs in on Tourmaline Bio FY2029 Earnings - MarketBeat
Bleakley Financial Group LLC Purchases 110 Shares of Choice Hotels International, Inc. (NYSE:CHH) - Defense World
In the crowded cardio space, it’s David vs. Goliath for small biotechs - PharmaVoice
Jennison Associates LLC Trims Stake in Tourmaline Bio, Inc. (NASDAQ:TRML) - MarketBeat
Tourmaline Bio Inc (TRML) Stock Showcases -13.66% 20-Day Moving Average - The News Heater
TRML’s Market Seesaw: Yearly Gains & Recent Declines – What to Expect? - The InvestChronicle
Solventum Corp (SOLV) Shares Down Despite Recent Market Volatility - The News Heater
Tourmaline Bio Inc (TRML) Becoming More Attractive for Investors - Knox Daily
In the Green: JBDI Holdings Ltd (JBDI) Closes at 0.65, Up/Down 11.02 from Previous Day - The Dwinnex
Closing Bell Recap: E.W. Scripps Co (SSP) Ends at 1.88, Reflecting a 6.82 Upturn - The Dwinnex
Post-Trade Analysis: Celldex Therapeutics Inc (CLDX) Slides -2.11, Closing at 23.15 - The Dwinnex
Tourmaline Bio Inc Stock (TRML) Financials Data
Revenue
Net Income
Cash Flow
EPS
Tourmaline Bio Inc Stock (TRML) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Kulkarni Sandeep Chidambar | CEO |
Aug 16 '24 |
Buy |
13.79 |
5,221 |
71,998 |
5,221 |
5.68%
0.28%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):